Technology that can detect when nerve cells fire, which can be used to observe nerve activity in the eye as well as other light-accessible parts of the body, has been created by researchers at Stanford University, according to a press release from the …
Author: Healio ophthalmology
Gene therapy fails to show clinical activity in X-linked retinoschisis
An investigational AAV-based gene therapy from Applied Genetic Technologies Corporation for X-linked retinoschisis due to mutations in the RS1 gene showed no signs of clinical activity at 6 months in a phase 1/2 trial, the company announced.The rAAV2tY…
VIDEO: Presbyopia correction: How to choose between EDOF, MTF or mix-and-match IOLs
NEW YORK — From OSN New York 2018, Maria C. Scott, MD, founder of Chesapeake Eye Care and Laser Center in Annapolis, Maryland, gives her presentation on how to choose between extended depth of focus, multifocal and mix-and-match IOLs.
Europe’s Luxturna approval tops November retina news
The European Commission’s approval of Luxturna for inherited retinal disease was the most-read retina-related article on Healio.com/OSN in November. Other top news included clinical trial updates from Clearside and Adverum.Here are the top five most-re…
Aerpio posts quarterly net income
Aerpio Pharmaceuticals reported a net income of $11.5 million, or $0.28 per share, in the third quarter of 2018 compared with a net loss of $4.6 million, or $0.17 per share, in 2017’s third quarter.Revenue was $18.8 million in the quarter compared with…
Quality of life improvements sustained in trial of GenSight’s LHON treatment
GS010 for Leber hereditary optic neuropathy demonstrated quality of life improvements in a phase 3 clinical trial, GenSight Biologics announced in a press release.The phase 3 REVERSE trial evaluated the safety and efficacy of a single intravitreal inje…
VIDEO: Nuclear disassembly: The new divide and conquer
NEW YORK — From OSN New York 2018, Jennifer Loh, MD, of Loh Ophthalmology Associates of Miami, gives her presentation on the miLOOP (IanTECH/Zeiss) for nuclear disassembly.
Anthem Blue Cross Blue Shield to cover Avedro’s corneal cross-linking
Anthem Blue Cross Blue Shield will cover Avedro’s Photrexa formulations and KXL System for corneal cross-linking, the company announced in a press release.This brings the number of commercial payers covering the procedure to 60, including the U.S.’s la…
AAO: Keep safety standards high in scope-of-practice expansions
The American Academy of Ophthalmology agrees with a joint federal report’s recommendations on scope of practice, the organization announced in a press release.The report, issued by the U.S. Department of Health and Human Services, the U.S. Department o…
Mazzo named OCTANe board chairman
OCTANe has appointed Jim Mazzo as the chairman of its board of directors, according to a press release.Mazzo, global president of ophthalmic devices at Carl Zeiss Meditec, will take over the 2-year term as of Jan. 1, 2019.“Jim has been a strong advocat…
How US-Canada-Mexico trade deal could impact drug prices, research
The United States-Mexico-Canada Agreement keeps biologic drug prices high but could potentially spur new research opportunities, a pharmaceutical expert told Healio Family Medicine.The agreement between the three countries announced on Nov. 30, but sti…
FDA approves Alembic’s allergic conjunctivitis treatment
The FDA has approved an abbreviated new drug application for olopatadine hydrochloride ophthalmic solution 0.1%, Alembic Pharmaceuticals announced in a press release.The solution is therapeutically equivalent to Patanol ophthalmic solution 0.1% (Novart…
Verkazia approved in Scotland for vernal keratoconjunctivitis in children, adolescents
The Scottish Medicines Consortium has approved Verkazia eye drop emulsion for the treatment of vernal keratoconjunctivitis in children from 4 years of age and adolescents, Santen UK Limited announced in a press release.Verkazia, which contains 0.1% cyc…
Akorn loses Fresenius appeal; CEO to step down
The Delaware Supreme Court upheld a lower court decision allowing Fresenius Kabi to back out of a $4.3 billion acquisition of Akorn, prompting Akorn CEO Raj Rai to step down, according to a press release.Akorn will begin a formal search for a new CEO a…
ProQR awarded innovation credit for development of LCA10 treatment
The Dutch government has awarded ProQR a 4.7 million euro innovation credit for the development of QR-110, the company’s Leber’s congenital amaurosis 10 treatment candidate, according to a release.Awarded through the RVO of the Ministry of Economic Aff…
OSN’s top news of the week
Here are the top stories on Healio.com/OSN this past week: FDA approves Dextenza for treatment of postoperative ocular painDextenza (dexamethasone ophthalmic insert 0.4 mg) is the first FDA-approved intracanalicular insert to deliver dexamethasone to t…
Read OSN’s Dec. 10 publication exclusives online
The Dec. 10 issue of Ocular Surgery News had a focus on the popularity of trifocal IOLs in Europe.Read five of the issue’s publication exclusives here: Cover StoryTrifocal IOLs rank high in European surgeons ’ preferencesAccording to many users, physic…
What to look forward to at Retina World Congress
The second Retina World Congress will take place in Fort Lauderdale, Florida, March 21 to 24, bringing retina specialists from across the globe together to interact and learn from each other.It will include case studies, panels, surgical videos and cli…
Carl Zeiss Meditec reports increased revenue for 2017/2018
Carl Zeiss Meditec reported revenue of 1,280.9 million euros for fiscal year 2017/2018, an increase of 7.6% over the previous year’s revenue of 1,189.9 million euros.Earnings before interest and taxes increased from 180.8 million euros to 197.1 million…
Novartis, Intellia expand collaboration for CRISPR/Cas9-based products
Intellia Therapeutics and Novartis are expanding their cell therapy collaboration agreement to include the ex vivo development of therapies using certain ocular stem cells, according to a press release.Novartis will be able to use these stem cells to d…